http://orcid.org/0000-0002-4990-0961
References
- Nalepa G, Clapp DW. Fanconi anaemia and cancer: an intricate relationship. Nat Rev Cancer. 2018;18(3):168–185.
- Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–424.
- Ciccia A, Ling C, Coulthard R, et al. Identification of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM. Mol Cell. 2007;25(3):331–343.
- Deans AJ, West SC. FANCM connects the genome instability disorders Bloom’s Syndrome and Fanconi anemia. Mol Cell. 2009;36(6):943–953.
- Bogliolo M, Bluteau D, Lespinasse J, et al. Biallelic truncating FANCM mutations cause early-onset cancer but not Fanconi anemia. Genet Med. 2018;20(4):458–463.
- Catucci I, Osorio A, Arver B, et al. Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility. Genet Med. 2018;20(4):452–457.
- Peterlongo P, GENESIS, Catucci I, Colombo M, et al. FANCM c.5791C > T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. Hum Mol Genet. 2015;24(18):5345–5355.
- Neidhardt G, Hauke J, Ramser J, et al. Association between loss-of-function mutations within the FANCM gene and early-onset familial breast cancer. JAMA Oncol. 2017;3(9):1245–1248.
- Figlioli G, Bogliolo M, Catucci I, et al. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. NPJ Breast Cancer. 2019;5(1):38.
- Kiiski JI, Pelttari LM, Khan S, et al. Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer. Proc Natl Acad Sci USA. 2014;111(42):15172–15177.